Combination treatment for Epstein-Barr virus-related lymphoma that has returned
Part of Cancer, Immune system & allergy, Infections clinical trials.
This study tests a combination of four drugs (an immunotherapy called a PD-1 inhibitor, an antiviral drug called tenofovir, and two other targeted therapies) for people whose EBV-related lymphoma has come back or not improved after treatment. The goal is to see if this combination can control the disease and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of an Epstein-Barr virus (EBV)-linked lymphoproliferative disorder (a condition where white blood cells grow out of control). This must have been proven by a biopsy test (positive for EBER, EBNA, or LMP1/2).
- You are 75 years old or younger and able to carry out daily activities with some help (ECOG performance status of 0, 1, or 2).
- You have at least one measurable area of disease — for example, a lymph node that is at least 1.5 cm wide, or an outside-the-node area that is at least 1 cm wide. Or, you have at least 20% of certain infected white blood cells in your blood.
- Your doctor expects you to live at least 3 more months.
- You are willing to follow the study schedule and give your informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (PD-1 inhibitor, tenofovir, chidamide, and lenalidomide) to treat diseases caused by the Epstein-Barr virus (EBV). The goal is to see if this combination can reduce the virus and improve symptoms.
This is an early-stage study testing a new immune-based treatment for people with conditions caused by the Epstein-Barr virus (EBV), such as chronic active EBV or post-transplant lymphoproliferative disease. The study aims to see if the treatment is safe and can help control the disease.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
Hear when a new PD-1 Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.